Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories

Executive Summary

In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.

You may also be interested in...



Generic Labeling Problems Targeted In US FDA Budget Request

Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.

US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.

US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA

Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.

Related Content

Topics

UsernamePublicRestriction

Register

PS057060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel